---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-25-000012"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T22:33:06.643382+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma Q4 net rev $190.6M (+44.8%), adj EPS $1.63; raises 2025 guidance

## Summary
- Record Q4 net rev $190.6M (+44.8% YoY); organic growth (ex-Alimera) +23.8%.
- Rare Disease rev $87.0M: Cortrophin Gel $59.4M (+42.3%), ILUVIEN/YUTIQ $27.6M.
- Adj. non-GAAP EBITDA $50.0M (+65.7%); diluted GAAP loss per share $0.55.
- Adj. non-GAAP diluted EPS $1.63 vs $1.00 in prior year quarter.
- 2025 guidance raised: rev $756-776M, adj. EBITDA $190-200M, adj. EPS $6.12-6.49.

## SEC filing metadata
- accession: 0001023024-25-000012
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000012/0001023024-25-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000012/ani-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-25-000012
- JSON: https://secwatch.observer/filing/0001023024-25-000012.json
- Plain text: https://secwatch.observer/filing/0001023024-25-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.